Bullish
Kura Oncology announced positive results from its FIT-001 clinical trial for darlifarnib combined with adagrasib in treating KRAS G12C-mutated advance...
Bullish
Kura Oncology reported compelling first-in-human data from the FIT-001 clinical trial, showing strong clinical activity and a manageable safety profil...
Bullish
Kura Oncology reported positive Phase 1a clinical trial data for its darlifarnib and adagrasib combination therapy in KRAS G12C-mutated advanced solid...